Aptevo Therapeutics Inc.

09/16/2024 | Press release | Distributed by Public on 09/16/2024 06:48

Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.